Long-Acting GHRH Analog with Drug Affinity Complex | GH Axis Research Compound

For Research Use Only. Not for human or veterinary use. Not a drug, supplement, or food additive.

Intended exclusively for in-vitro and laboratory research by qualified investigators.

CJC-1295 DAC – 5mg
A Long-Acting GHRH Analog for Growth Hormone Axis Research

Category: Peptide Research Compounds / Endocrinology Research / GH Axis & IGF-1 Biology

Disclaimer

ATTENTION: PrimalResearchLabs.com products are intended for laboratory research and in-vitro studies only. All information presented is for educational and research purposes related to scientific investigation.

These products are strictly not for human or veterinary use, consumption, or diagnostic applications. They are not pharmaceuticals, food additives, or dietary supplements.

By purchasing from PrimalResearchLabs.com, you acknowledge that you are a qualified researcher operating in a controlled laboratory environment. Adhere to all applicable local, state, and federal laws and regulations regarding handling and use of research chemicals. Use appropriate personal protective equipment (PPE) and follow laboratory safety protocols.

Biology

CJC-1295 DAC is a synthetic analog of Growth Hormone Releasing Hormone (GHRH 1-29), engineered with a Drug Affinity Complex (DAC) to enable covalent binding to endogenous serum albumin after administration.

This albumin-binding mechanism extends the peptide’s half-life from minutes to approximately 5.8–8.1 days in research models, enabling sustained stimulation of the GH/IGF-1 axis without frequent dosing.

CJC-1295 DAC is distinguished from native GHRH and non-DAC variants by its unique pharmacokinetic profile, making it a precision research tool for studying prolonged GH secretion dynamics, pulsatility preservation, and downstream IGF-1 axis biology.

This product is intended solely for in-vitro and preclinical research use and is not for human or veterinary consumption.

Key Research Applications of CJC-1295 DAC

1. GH & IGF-1 Axis Pharmacodynamics Research

CJC-1295 DAC has been characterized in controlled pharmacodynamic studies through:

• Sustained GH Elevation: Single injection produced dose-dependent increases in mean plasma GH by 2- to 10-fold for 6+ days, outlasting native GHRH (Teichman et al., 2006).
• Prolonged IGF-1 Elevation: Plasma IGF-1 increased 1.5- to 3-fold for 9–11 days, with cumulative elevation maintained for up to 28 days after multiple doses.
• Extended Half-Life Confirmed: Half-life of 5.8–8.1 days due to DAC-mediated albumin binding, with no serious adverse reactions observed.

Supporting Studies:
Teichman, S.L. et al. (2006) — Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805
“After a single injection of CJC-1295, dose-dependent increases in GH and IGF-1 concentrations were observed, with IGF-1 remaining elevated for up to 28 days after multiple doses.”
PubMed – PMID: 16352683 | doi: 10.1210/jc.2005-1536

2. GH Pulsatility & Secretion Pattern Research

• Preserved GH Pulsatility: Physiologic GH pulsatility maintained one week after a single injection, distinguishing it from continuous GH infusion models.
• Trough GH Elevation: Enhanced nadir GH levels between pulses, increasing total IGF-1 production.
• Pituitary Somatotroph Research Tool: Ideal for studying pulsatile vs tonic GH secretion effects on downstream IGF-1 and metabolic markers.

Supporting Studies:
Ionescu, M. & Frohman, L.A. (2006) — Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797
“CJC-1295 increased trough and mean GH secretion and IGF-1 production with preserved GH pulsatility.”
PubMed – PMID: 17018654 | doi: 10.1210/jc.2006-1702

3. GH/IGF-1 Axis Biomarker & Serum Proteomics Research

• Serum Protein Profile Modulation: Proteomic analysis identified five protein spots with intensity changes, correlating an albumin fragment with IGF-1 levels, suggesting potential novel GH biomarkers.
• Apolipoprotein A1 & Transthyretin Modulation: Identified decreased intensity of these proteins post-administration, revealing new downstream serum protein changes.
• GH Biomarker Research: Used as a positive control in developing improved GH activity assays.

Supporting Studies:
Ramirez, R.J.L. et al. (2009) — Growth Hormone & IGF Research, 19(6), 535–541
“Proteomic analysis identified five protein spots with significant changes, including a linear correlation between an albumin fragment spot and IGF-1 levels.”
PubMed – PMID: 19386527 | doi: 10.1016/j.ghir.2009.02.006

Recommended Research Concentrations

For laboratory research reference only. Not for human or veterinary use.

Why Choose Primal Research for CJC-1295 DAC?

• ≥98% HPLC-verified purity — critical for GHRH receptor binding and somatotroph assay accuracy
• DAC modification integrity confirmed per batch — albumin-binding capacity verified
• Independent third-party batch testing with COA available
• Research-optimized 5mg quantity supporting extensive pharmacokinetic and pharmacodynamic protocols

Storage & Handling

• Store at -20°C, desiccated and protected from light
• Soluble in sterile water or bacteriostatic water
• Prepare fresh solutions prior to each experiment
• Avoid repeated freeze-thaw cycles — DAC modification is sensitive to degradation

Technical Specifications

• Compound: CJC-1295 DAC (DAC:GRF, Drug Affinity Complex:GRF)
• Molecular Weight: ~3647.3 Da
• Half-Life: 5.8–8.1 days (albumin-bound, in research models)
• Purity: ≥98% (HPLC Verified)
• Form: 5mg lyophilized powder
• Storage: -20°C, desiccated, light-protected
• Solubility: Soluble in sterile water or bacteriostatic water
• COA: Available per batch on request

Advance Your GH Axis Research

Order your 5mg vial of CJC-1295 DAC today to support advanced research in GH axis biology, IGF-1 signaling, and endocrine pharmacodynamics.

Primal Research products are sold strictly for in-vitro and laboratory research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease or condition. Purchasers are responsible for compliance with all applicable local, state, and federal regulations.